

# Opposing effects of $\beta$ -2 and $\beta$ -1 adrenergic receptor signaling on neuroinflammation and dopaminergic neuron survival in $\alpha$ -synuclein-mediated neurotoxicity

**Daniel Torrente**

University of Michigan Medical School

**Enming J. Su**

University of Michigan Medical School

**Gerald P. Schielke**

University of Michigan Medical School

**Mark Warnock**

University of Michigan Medical School

**Kris Mann**

University of Michigan Medical School

**Daniel A. Lawrence** (✉ [dlawrenc@umich.edu](mailto:dlawrenc@umich.edu))

University of Michigan Medical School

---

## Research Article

**Keywords:**  $\alpha$ -synuclein, Substantia nigra, Parkinson disease, Dopaminergic neurons, Propranolol, Clenbuterol, DSP-4, Xamoterol, Microglia, T-cell

**Posted Date:** June 22nd, 2022

**DOI:** <https://doi.org/10.21203/rs.3.rs-1766396/v1>

**License:**   This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

**Additional Declarations:** No competing interests reported.

---

**Version of Record:** A version of this preprint was published at Journal of Neuroinflammation on March 2nd, 2023. See the published version at <https://doi.org/10.1186/s12974-023-02748-3>.

# Abstract

## Background

Noradrenergic neurons in the locus coeruleus (LC) are the primary source of norepinephrine (NE) in the brain and degeneration of these neurons is reported in the early stages of Parkinson's disease (PD), even prior to dopaminergic neuron degeneration in the substantia nigra (SN), which is a hallmark of PD pathology. NE depletion is generally associated with increased PD pathology in neurotoxin-based PD models. The effect of NE depletion in other models of PD like  $\alpha$ -synuclein-based models is largely unexplored. In PD models and in human patients,  $\beta$ -adrenergic receptors (AR) signaling is associated with a reduction of neuroinflammation and PD pathology. However, the effect of NE depletion in the brain and the extent of NE and  $\beta$ -ARs signaling involvement in neuroinflammation, and dopaminergic neuron survival is poorly understood.

## Methods

Two mouse models of PD, a 6OHDA neurotoxin-based model and a human  $\alpha$ -synuclein (h $\alpha$ -SYN) virus-based model of PD were used. DSP-4 was used to deplete NE levels in the brain and its effect was confirmed by HPLC with electrochemical detection. A pharmacological approach was used to mechanistically understand the impact of DSP-4 in the h $\alpha$ -SYN model of PD using a norepinephrine transporter (NET) and a  $\beta$ -AR blocker. Epifluorescence and confocal imaging were used to study changes in microglia activation and T-cell infiltration after  $\beta$ 1-AR and  $\beta$ 2-AR agonist treatment in the h $\alpha$ -SYN virus-based model of PD.

## Results

Consistent with previous studies we found that DSP-4 pretreatment increased dopaminergic neuron loss after 6OHDA injection. In contrast, DSP-4 pretreatment protected dopaminergic neurons after h $\alpha$ -SYN overexpression. DSP-4-mediated protection of dopaminergic neurons after h $\alpha$ -SYN overexpression was dependent on  $\beta$ -AR signaling since using a  $\beta$ -AR blocker prevented DSP-4-mediated dopaminergic neuron protection in this model of PD. Finally, we found that the  $\beta$ -2AR agonist, clenbuterol, reduced microglia activation, T-cell infiltration, and dopaminergic neuron degeneration whereas xamoterol a  $\beta$ -1AR agonist showed increased neuroinflammation and dopaminergic neuron degeneration in the context of h $\alpha$ -SYN-mediated neurotoxicity.

## Conclusion

Our data demonstrate that the effects of DSP-4 on dopaminergic neuron degeneration are model specific, and suggest that in the context of  $\alpha$ -SYN driven neuropathology  $\beta$ 2-AR specific agonists may have

therapeutic benefit in PD.

## Background

Parkinson's disease (PD) is characterized by the abnormal accumulation of  $\alpha$ -synuclein ( $\alpha$ -Syn) in neuronal cell bodies and the progressive loss of dopaminergic neurons in the substantia nigra *pars compacta* (SNpc). Besides dopaminergic neurons, degeneration of other neuronal populations is known to contribute to PD symptoms and pathology, including noradrenergic neurons located in the locus coeruleus (LC) [1]. LC-Noradrenergic neurons are the main source of norepinephrine (NE) in the brain and degeneration of these neurons is reported to precede dopaminergic neuron loss in PD patients [1–3]. However, the role of the NE system in PD pathology and in dopaminergic neuron survival is poorly understood.

The outcomes resulting from perturbations of the NE system in the central nervous system (CNS) and in PD pathology are complex. For instance, in neurotoxin-based models of PD, reduction of brain NE is shown to increase neuroinflammation and dopaminergic neuron degeneration in the SNpc [4–6], while other studies find no effect on dopamine levels or dopaminergic neuron survival after brain NE depletion [7–10]. Outside of PD pathologies, depletion of brain NE has been reported to be neuroprotective by reducing microglia activation [11]. These diverse responses reflect the many and complex physiological functions regulated by NE in the brain [12, 13]. NE signaling is primarily driven by different G protein-coupled receptors, such as  $\alpha$ -1,  $\alpha$ -2,  $\beta$ -1, and  $\beta$ -2 adrenergic receptors (AR) which are proposed to regulate different functions in the CNS such as wakefulness, attention, and neuroinflammation [12–14]. In PD, a special clinical interest is focused on  $\beta$ -ARs signaling, since PD animal models and human patients show a link between promoting  $\beta$ -ARs signaling and a reduction of PD risk and pathology whereas blocking  $\beta$ -ARs is associated with increased PD risk [15–18]. However, the mechanisms associated with NE and  $\beta$ -ARs signaling on dopaminergic neuron survival is still elusive.

The selective noradrenergic neurotoxin, DSP-4, is the most common and widely accepted approach to deplete NE levels in the CNS [19]. The correlation between brain NE depletion by DSP-4 and increased dopaminergic neuron degeneration in the SNpc is mainly founded on neurotoxin-based models of PD [4–6], while other animal models representing different pathological features of PD have not been extensively studied. In the present work, we explored the effects of NE depletion in the CNS using DSP-4 in a human  $\alpha$ -SYN (h $\alpha$ -SYN) viral-based mouse model of PD with the goal to identify novel therapeutic targets that involve the NE system in the context of h $\alpha$ -SYN-mediated neurotoxicity.

## Materials And Methods

### Mice

Male WT C57BL/6J mice between 8 and 14 weeks old were used in all experiments and were obtained from Jackson Laboratories. Mice were housed under a 12-hour light/dark cycle with free access to water

and standard rodent chow. All animal procedures were approved by and carried out in accordance with the guidelines of the Institutional Animal Care and Use Committee at the University of Michigan.

### **Stereotaxic 6OHDA injection**

Mice were anesthetized with 2% isoflurane and secured on a stereotactic frame. 6-hydroxydopamine (6OHDA; 2547; Tocris) was dissolved in a 0.2% ascorbic acid saline solution. WT mice received a unilateral injection of 6OHDA in the striatum. The striatum coordinate used for stereotaxic injection was AP= 0.7 ML=2.0 DV=-2.0 mm. A total of 5 ug of 6OHDA in 2  $\mu$ L was injected in the striatum at a rate of 0.5  $\mu$ L/min with a 33G nanofil blunt needle (NF33BL-2, World Precision Instruments) connected to FEP tubing and a 25uL Hamilton syringe. After 6OHDA infusion, the nanofil blunt needle was left in place for 5 min. 4 weeks after injection, mice were PBS and 4% PFA perfused for immunohistochemistry analysis.

### **rAAV2-h $\alpha$ -SYN design and production**

Recombinant adeno-associated virus serotype 2 (rAAV2) expressing human wild-type  $\alpha$ -SYN (rAAV2-h $\alpha$ -SYN) or rAAV2-empty (rAAV2-control) virus were produced at the University of Michigan Vector core. Cloning of h $\alpha$ -SYN was done using the pAAV-h $\alpha$ -SYN WT plasmid as a template (#36055, Addgene) and the pAAV-CBA plasmid as the vector backbone (#81008; Addgene). The resulting plasmid pAAV-CBA-h $\alpha$ -SYN was used to produce rAAV2-h $\alpha$ -SYN virus where h $\alpha$ -SYN expression is driven by the chicken-beta actin (CBA) promoter. The final titers of the viral stocks were determined by qPCR and ranged between 2.0 x 10<sup>13</sup> and 3.12 x 10<sup>13</sup> viral genome copies per milliliter (vg/mL; plasmids and viruses are available at the University of Michigan Vector core).

### **Stereotaxic rAAV2-h $\alpha$ -SYN injection in SN**

Mice were anesthetized with 2% isoflurane and secured on a stereotactic frame. WT mice received a unilateral injection of rAAV2-h $\alpha$ -SYN at a final concentration of 2 x 10<sup>13</sup> vg/mL into the SN. The SN coordinate used for stereotaxic injection was AP=-3.1 ML=-1.4 DV=-4.2 mm. A total of 2  $\mu$ L of rAAV2-h $\alpha$ -SYN virus was injected in the SN at a rate of 0.25  $\mu$ L/min with a 33G nanofil blunt needle (NF33BL-2, World Precision Instruments) connected to FEP tubing and a 25uL Hamilton syringe. After rAAV2-h $\alpha$ -SYN virus infusion, the nanofil blunt needle was left in place for 5 min. 4 weeks after injection, mice were PBS and 4% PFA perfused for immunohistochemistry analysis.

### **Drug treatments**

N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine hydrochloride (DSP-4) was prepared in saline solution and injected IP in a single dose of 50 mg/Kg (2958; Tocris). This dose was selected based on previous studies showing tissue NE depletion in the brain (Ross and Stenfors, 2015). 3 days after DSP-4 treatment stereotaxic injection of 6OHDA or rAAV2-h $\alpha$ -SYN injection was performed as described above. To block the norepinephrine transporter (NET) we use Desipramine (D3900; Sigma). A single dose of Desipramine (25 mg/Kg in saline solution) was delivered IP 45 min prior to DSP-4 treatment. Propranolol was delivered

IP daily at 10 mg/Kg in saline solution (0624; Tocris). Propranolol treatment started 45 min after stereotaxic injection of rAAV2-ha-SYN injection and was given once a day until the end of the experiment. Xamoterol (3 mg/Kg; IP) (24267; Cayman) and Clenbuterol (10 mg/Kg; IP) (C5423, Sigma) daily treatment was performed 45 min after stereotaxic injection of rAAV2-ha-SYN injection for 4 weeks until the end of the experiment. All drugs used here were dissolved fresh using saline solution the day of treatment and saline solution was used as vehicle control in all experimental conditions. Clenbuterol and xamoterol doses were selected based on previous studies related to CNS pathologies (Mittal *et al.*, 2017; Faizi *et al.*, 2011).

## **NE and Serotonin measurements**

The SN and cortex of WT mice 4 weeks after saline, DSP-4 or Desipramine + DSP-4 treatments were dissected and snap-frozen in liquid nitrogen. Then, samples were sonicated on ice by probe sonication on setting 3 with a 30% duty cycle in ice-cold 0.1M PCA containing 0.1 mM EDTA. Samples were centrifuged at  $10,000 \times g$  for 10 minutes at 4°C. Then, supernatants were transferred into fresh 0.22  $\mu$ M PVDF microcentrifuge filter tubes. NE and Serotonin concentrations were determined by reverse-phase high-performance liquid chromatography (HPLC) with electrochemical detection (HPLC-ED). For HPLC, an ESA 5600A CoulArray detection system, equipped with an ESA Model 584 pump and an ESA 542 refrigerated autosampler was used. Separations were performed at 26°C using an MD-150  $\times$  3.2 mm C18 column. The mobile phase consisted of 1.6 mM 1-octane sulfonic acid sodium, 75 mM NaH<sub>2</sub>PO<sub>4</sub>, 0.025% triethylamine, and 8% acetonitrile at pH 3.0. The samples were eluted isocratically at 0.4 mL/min and detected using a 6210 electrochemical cell (ESA, Bedford, MA) equipped with a 5020-guard cell. Guard cell potential was set at 600 mV, while analytical cell potentials were -175, 150, 350 and 425 mV. The total run time for each run is 40 min. The analytes were identified by the matching criteria of retention time to known standards (Sigma Chemical Co., St. Louis MO). NE and serotonin were quantified by comparing peak areas to those of standards on the dominant sensor. Data were normalized by protein concentration in each brain sample.

## **Immunohistochemistry**

For immunofluorescence, mice were PBS and 4% PFA-perfused, brains were harvested, post-fixed in PFA, dehydrated in 30% sucrose and embedded in OCT. 14 $\mu$ m-thick frozen sections were permeabilized and blocked in 0.5% TritonX-100 and 5% Bovine Serum Albumin in 0.5% TritonX-100/1X PBS, respectively. Sections were incubated with primary antibodies in blocking solution overnight at 4°C followed by incubation with 488, 564 and 647 Alexa-Fluor conjugated secondary antibodies for 1h at room temperature. After secondary antibody incubations sections were washed with 0.1% NP-40/1X PBS. DAPI was used to detect cells nuclei. Sections were mounted using ProLong™ Diamond Antifade Mountant (P36961; Life Technologies). The primary antibodies used were: Tyrosine Hydroxylase (TH) (1:1000; ab113, Abcam), ha-SYN (1:300; ab138501, Abcam), TMEM119 (1:500; ab209064, Abcam), CD16/32 (1:100; #101301, BioLegend) and CD3 (1:200; 100347, BioLegend). For staining involving ha-SYN, heat-mediated antigen retrieval was performed using DAKO retrieval solution (S1700; DAKO). All images were

acquired with a Nikon Ti-E Eclipse Microscope using a 20x objective (Plan-Apo, 0.75 numerical aperture) or a 60x oil objective (Plan-Apo, 1.4 numerical aperture). Confocal images were acquired using CREST X-Light V2 Spinning Disk. Z-stacks of 60x images were collected at 0.5  $\mu\text{m}$  increments with a total thickness of  $\sim 6 \mu\text{m}$ . Images were captured with an ORCA-fusion camera (C14440-20UP, Hamamatsu) or an Andor Zyla camera (Zyla 4.2 sCMOS, Oxford Instruments). Large scan function with Z step focus was used to capture stitched images of the SN using a 20x objective. Confocal images are shown as maximum intensity projection images. Images are representative of the respective staining and were processed and analyzed using NIS-elements advanced research software (Nikon Instrument Inc) and FIJI-Image J open software.

### **Quantification of dopaminergic neurons**

Estimation of dopaminergic neuron degeneration in the SN was performed by counting the total number of TH<sup>+</sup> neurons in the injected and uninjected SN 4 weeks after rAAV2-h $\alpha$ -SYN. 14 $\mu\text{m}$ -thick coronal brain sections were sampled at intervals of 112  $\mu\text{m}$  through the rostrocaudal extent of the SN, at least 4 sections per mouse were counted. The total number of TH<sup>+</sup> neurons (Nt) in the injected and uninjected hemisphere of the SN were estimated using model-based stereology incorporating the Abercrombie correction with the following formula:  $Nt = Ns \times (St/Ss) \times M/(M + D)$ , where Ns is the total number of neuron counted, St is the total number of sections in the brain region, Ss is the number of sections sampled, M is the thickness of the section, and D is the average diameter of the counted neurons [20]. The average diameter of TH neurons was calculated averaging the min and max Feret diameter. Nt for the uninjected SN was used as an internal control in every mouse and a % of dopaminergic neuron survival was obtained using the following formula: TH<sup>+</sup> neuron survival (%) =  $(Nt_{\text{injected SN}} / Nt_{\text{uninjected SN}}) \times 100$ . The genotype of mice was unknown to the investigator at the time of quantification.

### **Fluorescence intensity quantification**

Fluorescence intensity of TMEM119 and CD16/32 in the injected and uninjected SN 4 weeks after rAAV2-h $\alpha$ -SYN virus injection was performed as follows: 14 $\mu\text{m}$ -thick coronal brain sections co-stained with TH, TMEM119 and CD16/32 were sampled on intervals of 112  $\mu\text{m}$  through the rostrocaudal extent of the SN, 4 sections per mouse were quantified. A region of interest defining the entire SN *pars compacta* (SNpc) using TH co-staining was used to quantify the sum fluorescence intensity above background in the injected and uninjected SN. A relative fluorescence value was calculated in each mouse using the uninjected SN as an internal control. For the average number of CD3<sup>+</sup> cells quantification in the SN 4 weeks after rAAV2-h $\alpha$ -SYN injection, 14 $\mu\text{m}$ -thick coronal brain sections were stained with CD3 and TH. The average number of CD3<sup>+</sup> cells associated with the SNpc were counted by defining the SNpc using TH staining and the average number of CD3<sup>+</sup> cells were then estimated in the injected and uninjected (rarely observed) SNpc in 4 sections per mouse sampling the rostrocaudal extent of the SN.

### **Corridor task**

Lateralized sensory-motor integration was measured using a corridor task. This behavioral test was selected due to its sensitivity to detect partial unilateral dopaminergic neuron damage in rats and mouse PD models [21, 22], which is ideal for the mild unilateral degeneration of dopaminergic neurons observed in the SN after rAAV2-hα-SYN injection. This test consists in a long narrow rectangular plexiglass corridor with the following dimensions: L=60 cm x W=4 cm x H=15 cm (testing corridor). The testing corridor contains 10 pairs of adjacent Eppendorf caps placed at 5-cm intervals with 4-5 sugar pellets each (20 mg; TestDiet). A corridor without Eppendorf caps with the same dimensions as the testing corridor was used as the habituation corridor. WT mice treated with clenbuterol or saline daily after rAAV2-hα-SYN virus injection were habituated 1 day before the end of the experiment (4 weeks after injection) in the habituation corridor by scattering sugar pellets along the corridor floor and allowing them to freely explore for 10 min. Lateralized sensory-motor integration was tested 4 weeks after rAAV2-hα-SYN injection. On the testing day, mice were placed in the habituation corridor for 5 min in the absence of sugar pellets, then mice were transferred to one end of the testing corridor containing sugar pellets and video recorded for 5 min. The video recordings were analyzed by an investigator blinded to the treatment and genotype. The number of ipsilateral and contralateral explorations relative to the injected hemisphere were counted until the mouse made a total of 20 explorations or the video ended. An exploration was defined as a nose-poke into an Eppendorf cap, whether the sugar pellet was poked or eaten, and a new exploration was only counted by exploring a new cap. Data is expressed as a percentage of bias lateralized explorations, calculated as:  $\text{Bias (\%)} = 100 * (\text{ipsilateral} - \text{contralateral}) / (\text{ipsilateral} + \text{contralateral})$ .

## Statistics

Data analysis was performed using GraphPad Prism 8 statistical software (GraphPad Software, La Jolla, CA, USA). All experiments were repeated at least two independent times and n indicates the number of individual mice used in the study. For statistical analysis, in any experiment with only two groups, a two-tailed t-test was used. For experiments with more than two groups, a one-way ANOVA with Tukey or Dunnett post hoc test was used. Data is represented as mean values  $\pm$  S.E.M;  $p < 0.05$  was considered significant.

## Results

# DSP-4 pretreatment increases dopaminergic neuron degeneration in the 6OHDA model of PD

Based on the conflicting results obtained by others using DSP-4 in neurotoxin-based models of PD, DSP-4 treatment either enhanced dopaminergic neuron degeneration [4–6] or failed to disrupt dopamine levels in the brain [23]. We first wanted to confirm the effects of reducing brain NE levels on dopaminergic neuron survival by DSP-4 pretreatment (50 mg/Kg; IP) in the 6OHDA neurotoxin-based mouse model of PD. Consistent with previous reports [4–6], DSP-4 pretreatment in WT mice showed a significant increase in dopaminergic neuron degeneration compared to saline-treated WT mice 4 weeks after striatal 6OHDA

injection (Fig. 1A,B). DSP-4 is proposed to lead to NE depletion in the brain by first interacting with the norepinephrine transporter (NET) in noradrenergic terminals [19]. To test whether DSP-4-mediated degeneration of dopaminergic neurons in the 6OHDA model of PD is dependent on DSP-4 interaction with NET, we use desipramine, a reversible NET blocker [24]. Desipramine treatment (25 mg/Kg; IP) 45 min prior to DSP-4 treatment in WT mice showed a significant reduction in dopaminergic neurons degeneration compared to only DSP-4-treated WT mice 4 weeks after 6OHDA injection (Fig. 1A,B). To confirm the effect of DSP-4 in brain NE levels, we measure NE tissue levels in the SN and cortex of WT mice using high performance liquid chromatography with electrochemical detection (HPLC-ED) 4 weeks after DSP-4 treatment. In WT mice, DSP-4 treatment led to a reduction in NE levels in tissue extracts obtained from the SN and cortex. No effect was observed in serotonin levels after DSP-4 treatment in the SN or cortex (Fig. 1C). Recent reports indicate that NE tissue level reduction after DSP-4 treatment is not associated with noradrenergic neuron degeneration in the LC at early time points (less than 3 months after DSP-4 injection) [25]. To test whether reduction of NE tissue levels in the SN and cortex correlates with noradrenergic neuron loss in the LC 4 weeks after DSP-4 treatment, we stained coronal sections of the LC and quantified TH+ neurons in the LC. Consistent with previous reports, no significant reduction in TH+ noradrenergic neurons cell bodies were detected 4 weeks after injection of DSP-4 (Fig. 1D). Overall, these data confirm previous reports of DSP-4 promoting dopaminergic neuron degeneration and suggest that DSP-4 interaction with NET is necessary to induce dopaminergic neuron degeneration in the context of 6OHDA-mediated damage.

### **DSP-4 treatment protects dopaminergic neurons degeneration in the SN from $\alpha$ -SYN-mediated degeneration.**

We showed that DSP-4 pretreatment promotes dopaminergic neuron degeneration in the 6OHDA neurotoxin-based mouse model of PD. Next, we tested whether reduction of NE tissue levels in the brain using DSP-4 will have the same effects on dopaminergic neuron survival in a  $\alpha$ -SYN mouse model of PD, where overexpression of  $\alpha$ -SYN is achieved by using a rAAV2 virus (rAAV2-  $\alpha$ -SYN). Surprisingly, DSP-4 pretreatment (50 mg/Kg; IP) in WT mice showed significant protection of dopaminergic neurons compared to saline-treated WT mice 4 weeks after  $\alpha$ -SYN overexpression (Fig. 2A-C). This result was opposite to the observed effect of DSP-4 in the 6OHDA mouse model of PD (Fig. 1A,B). Additionally, desipramine pretreatment (25 mg/Kg; IP) in DSP-4-treated WT mice prevented the protection of dopaminergic neurons in the SN compared to only DSP-4-treated WT mice 4 weeks after  $\alpha$ -SYN overexpression (Fig. 2A,B). We confirmed that desipramine pretreatment blocked the reduction of NE tissue levels after DSP-4 treatment in WT mice 4 weeks after DSP-4 injection using HPLC-ED (Fig. 2C). To discard the possibility that DSP-4-mediated protection was due to lack of  $\alpha$ -SYN expression in dopaminergic neurons we confirmed the presence of  $\alpha$ -SYN in dopaminergic neurons using an antibody specific for  $\alpha$ -SYN (Additional File 1: Fig. S1). These data suggest that DSP-4 mediated protection of dopaminergic neurons is NET-dependent and not the result of an off-target effect of DSP-4 facilitating dopaminergic neuron protection in the context of  $\alpha$ -SYN-mediated neurotoxicity.

## **Blocking $\beta$ -adrenergic receptors inhibits DSP-4-mediated dopaminergic neurons protection after $\alpha$ -SYN overexpression.**

DSP-4 is proposed to be a potent neurotoxin leading to depletion of brain NE and enhancing dopaminergic neuron degeneration in neurotoxin-based mouse models of PD [4–6]. However, this does not seem to apply in the  $\alpha$ -SYN virus-based mouse model of PD (Fig. 2). Reports indicate that after DSP-4 treatment tissue levels of NE are depleted whereas extracellular NE levels are increased in the brain [26–28]. This suggests that DSP-4 could enhance extracellular NE signaling which has been reported to be neuroprotective in different CNS pathologies, including PD [12, 13, 16–18]. In particular,  $\beta$ 2-AR signaling has been associated with a reduction in dopaminergic neuron degeneration in the MPTP and lipopolysaccharide (LPS) mouse model of PD [16, 18]. Additionally, promoting  $\beta$ -1 signaling is shown to be neuroprotective in mouse model of Alzheimer's diseases (AD) and Down's syndrome [29–31]. To test whether either of these two  $\beta$ -ARs could be involved in DSP-4-mediated protection of dopaminergic neurons in the SNpc, we used propranolol, a non-selective  $\beta$ -AR inhibitor, this antagonist blocks both  $\beta$ -1 and  $\beta$ -2 ARs [32]. Propranolol was given daily (10 mg/Kg; IP) after rAAV2- $\alpha$ -SYN injection in the SN of WT mice pretreated with DSP-4 or saline. We found that daily treatment of propranolol in DSP-4-treated WT mice inhibited dopaminergic neuron protection compared to only DSP-4-treated WT mice 4 weeks after  $\alpha$ -SYN overexpression (Fig. 3A,B). DSP-4 treatment alone showed significant protection of dopaminergic neurons compared to saline-treated WT mice after  $\alpha$ -SYN overexpression. There was no significant difference in dopaminergic neuron degeneration among saline-treated, propranolol + DSP-4-treated and only propranolol-treated WT mice 4 weeks after rAAV2- $\alpha$ -SYN injection (Fig. 3A,B). The presence of  $\alpha$ -SYN in dopaminergic neurons was confirmed in all experimental conditions using an antibody specific for  $\alpha$ -SYN (Additional File 1: Fig. S2). Overall, these data suggest that DSP-4 mediated protection of dopaminergic neurons in the SN involves signaling through the  $\beta$ -ARs in the context of  $\alpha$ -SYN-mediated neurotoxicity.

## **$\beta$ -2 but not a $\beta$ -1 AR agonist protects dopaminergic neurons in the SN from $\alpha$ -SYN-mediated neurotoxicity.**

Based on the observation that DSP-4 protects dopaminergic neuron degeneration presumably by increasing  $\beta$ -ARs signaling (Fig. 3). We wanted to explore whether  $\beta$ -1 or  $\beta$ -2 AR signaling was driving dopaminergic neuron protection in the context of  $\alpha$ -SYN-mediated neurotoxicity. To test this, we used Xamoterol and Clenbuterol, a  $\beta$ -1 and a  $\beta$ -2 AR agonist, respectively [33, 34]. Daily treatment of Clenbuterol (10 mg/Kg; IP) showed significant protection of dopaminergic neurons compared to saline and Xamoterol-treated WT mice 4 weeks after overexpression of  $\alpha$ -SYN (Fig. 4A,B). Interestingly, daily treatment of Xamoterol (3 mg/Kg; IP) showed a significant increase of dopaminergic neuron degeneration compared to saline-treated WT mice 4 weeks after rAAV2- $\alpha$ -SYN injection (Fig. 4A,B). The presence of  $\alpha$ -SYN in dopaminergic neurons was confirmed in all experimental conditions using an antibody specific for  $\alpha$ -SYN (Additional File 1: Fig. S3). Overall, these data suggest that signaling by  $\beta$ -1 and  $\beta$ -2 AR may have opposing effects in the context of  $\alpha$ -SYN-mediated neurotoxicity since promoting  $\beta$ -2 AR signaling is neuroprotective whereas  $\beta$ -1 AR signaling is neurodegenerative.

## **Opposite effects of $\beta$ -1 and $\beta$ -2 AR signaling in microglia activation after $\alpha$ -SYN overexpression in the SN.**

In PD,  $\beta$ -2 AR signaling is associated with a reduction in microglia activation *in vivo* and *in vitro* [18, 35, 36]. In human and animal models of PD, microglia activation is suggested to contribute to the degeneration of dopaminergic neurons in the SNpc [37]. To explore whether Clenbuterol-mediated protection of dopaminergic neurons after  $\alpha$ -SYN overexpression was associated with a reduction in microglia activation in the SN, we stained coronal brain sections of the SN with CD16/32, TMEM-119 and TH 4 weeks after rAAV2- $\alpha$ -SYN injection. CD16/32 was used as a proinflammatory marker of microglia [38, 39] and TMEM-119 was used as a marker of microglia [40]. We observed that Clenbuterol treatment significantly reduced CD16/32 immunoreactivity in the SN compared to saline-treated WT mice whereas Xamoterol treatment significantly increased both, CD16/32 and TMEM-119 immunoreactivity compared to saline-treated WT mice 4 weeks after rAAV2- $\alpha$ -SYN injection (Fig. 5A-C). Clenbuterol treatment did not significantly reduce TMEM-119 immunoreactivity compared to saline-treated WT mice (Fig. 5A-C). Confocal images showed that pro-inflammatory microglia (CD16/32 + and TMEM119 + cells) were in close contact with dopaminergic neuron cell bodies and axons in saline-treated and Xamoterol-treated WT mice but not in Clenbuterol-treated WT mice 4 weeks after rAAV2- $\alpha$ -SYN injection (Fig. 5D). These data suggest that promoting  $\beta$ -2 AR signaling reduces proinflammatory microglia whereas promoting  $\beta$ -1 AR signaling enhance microglia proinflammatory response in the context of  $\alpha$ -SYN-mediated damage.

## **$\beta$ -2 AR agonist reduce T-cell infiltration and rescues behavioral deficits after $\alpha$ -SYN overexpression in the SN**

In human patients and mouse models of PD, T-cell infiltration has been associated with dopaminergic neuron degeneration and PD pathology [41]. In the  $\alpha$ -SYN-based model of PD, T-cell infiltration is proposed to be a necessary step to induce dopaminergic neuron degeneration in the SNpc [42, 43]. To test if  $\beta$ -1 or  $\beta$ -2 AR signaling using xamoterol and clenbuterol, respectively affected T-cell infiltration in the SN 4 weeks after rAAV2- $\alpha$ -SYN injection, we stained coronal sections of the SN with TH and the T-cell marker, CD3. We found that clenbuterol treatment significantly reduced the infiltration of T-cell associated with dopaminergic neurons cell bodies and axons in the SNpc compared to saline-treated WT mice 4 weeks after rAAV2- $\alpha$ -SYN injection (Fig. 6A-C). In contrast, Xamoterol treatment significantly increased T-cell infiltration compared to saline-treated WT mice 4 weeks after rAAV2- $\alpha$ -SYN injection (Fig. 6A-C). To assess whether the neuroprotection associated with Clenbuterol treatment rescues behavioral deficits after rAAV2- $\alpha$ -SYN injection, a lateralized sensory-motor integration test was used. This behavioral test measures the lateralized bias of exploring sugar pellets in a corridor task and it has been shown to be sensitive in detecting partial unilateral dopaminergic neuron damage [21, 44]. Clenbuterol treatment prevented the behavioral deficit in WT mice 4 weeks after overexpression of  $\alpha$ -SYN compared to saline-treated WT mice (Fig. 6D). Overall, our data showed that stimulation of the  $\beta$ -2 AR using clenbuterol reduced neuroinflammation and protected dopaminergic neuron degeneration whereas stimulation of the  $\beta$ -1 AR using xamoterol promoted neuroinflammation and dopaminergic neuron degeneration in the

context of  $\alpha$ -SYN mediated neurotoxicity. This suggests that a selective  $\beta$ -2 AR agonist but not a  $\beta$ -1 AR agonist may be preferred as a possible treatment in PD.

## Discussion

NE regulates different physiological and pathological functions in the CNS, the NE system is affected in PD patients and  $\beta$ 2-AR signaling has been associated with a reduction in PD risk, whereas inhibition of  $\beta$ -AR signaling has been associated with an increase in PD risk. However, the role of NE signaling on dopaminergic neuron survival in the SNpc has not been yet elucidated. In this paper, we used a 6OHDA-based and  $\alpha$ -SYN-based model of PD to explore the effects of DSP-4 in dopaminergic neuron survival with the goal to better understand the role of NE signaling in PD pathology and to identify novel therapeutic approaches involving the NE system in PD. We found that DSP-4 pretreatment has different effects on dopaminergic neuron survival depending on the mouse model of PD used. In the 6OHDA PD model, DSP-4 increased dopaminergic neuron degeneration whereas, in the  $\alpha$ -SYN model of PD, DSP-4 treatment protected dopaminergic neurons. In both cases, DSP-4 interaction with NET was necessary to elicit their respective responses. Blocking the  $\beta$ -ARs using propranolol, inhibited DSP-4-mediated protection of dopaminergic neurons in the context of  $\alpha$ -SYN-mediated neurotoxicity. Finally, we identified that  $\beta$ 2-AR signaling is a likely therapeutic target in PD that reduced microglial activation, T-cell infiltration, and dopaminergic neuron degeneration. In contrast,  $\beta$ 1-AR signaling might be deleterious since xamoterol treatment increased neuroinflammation and dopaminergic neuron degeneration in the context of  $\alpha$ -SYN-mediated neurotoxicity.

We found that DSP-4 pretreatment protected dopaminergic neurons in the SNpc after  $\alpha$ -SYN overexpression. Our data conflicts with previous published studies in different PD mouse models PD [4–6, 45] and in other neurodegenerative diseases [46, 47]. These studies showed that DSP-4 pretreatment generally is associated with an increase in inflammation and neuronal degeneration. The DSP-4 dose used in this study is considered standard to elicit a robust depletion of NE tissue levels in the brain (single dose of 50mg/Kg; I.P) [19]. It is well known that DSP-4 treatment depletes NE tissue levels in the brain, but it is not well understood how DSP-4 affects extracellular NE levels in the brain. It's assumed that NE extracellular levels are reduced since NE tissue levels are depleted after DSP-4 treatment; however, some reports have challenged this idea, showing that DSP-4 treatment significantly increases extracellular levels of NE in the brain [19, 26–28]. This could explain our results showing DSP-4-mediated protection in the context of  $\alpha$ -SYN mediated neurotoxicity since increased NE signaling in the brain is associated with a reduction in neuroinflammation and neuronal degeneration *in vitro* and *in vivo* [48, 49]. This hypothesis is supported by the observation that blocking the  $\beta$ -ARs using propranolol, reverses DSP-4 protection of dopaminergic neurons after  $\alpha$ -SYN overexpression. However, further investigation is needed regarding the effects of DSP-4 treatment on extracellular NE levels in the brain and its role in modulating neuroinflammation and neuronal survival in different neurodegenerative diseases. Although, we found that DSP-4 protects from  $\alpha$ -SYN-mediated neurotoxicity, a recent study using a  $\alpha$ -SYN transgenic mouse model of PD shows that DSP-4 treatment failed to protect or enhance dopaminergic neuron degeneration in the SN compared to WT mice (Song et al., 2020). In this study, 13 months after DSP-4

treatment led to similar levels of dopaminergic neuron degeneration in the SN of both WT and  $\alpha$ -SYN transgenic mice [45]. This suggests that long term exposure to DSP-4 can lead to dopaminergic neuron degeneration in the SN in WT mice. The exact mechanism(s) of how DSP-4 may be leading to dopaminergic neuron degeneration in the SN is unknown.

A caveat with the hypothesis that increased extracellular NE might be driving DSP-4-mediated neuroprotection is that this fails to explain why DSP-4 pretreatment is not neuroprotective in other mouse models of PD, like the 6OHDA and LPS mouse model of PD [4–6]. A possibility that needs further investigation is that in these models of PD the expression of different ARs could be upregulated or downregulated favoring different NE signaling pathways that could exacerbate neurodegeneration after DSP-4 treatment. For instance, intraventricular injection of 6OHDA is reported to increase the density of  $\beta$ 1-AR and to a lesser extent  $\beta$ 2-AR in different brain regions, like the cortex and amygdala [50, 51]. Additionally, bilateral injection of 6OHDA in the SN induced the expression of  $\beta$ 1-AR in the gastrointestinal system which is associated with gastrointestinal dysmotility a non-motor symptom in PD [52]. Considering that  $\beta$ 1-AR signaling increased neuroinflammation and dopaminergic neuron degeneration in the  $\alpha$ -SYN mouse model of PD (Fig. 4–6), it is possible that 6OHDA injection in the striatum could change  $\beta$ -AR expression patterns in the brain favoring  $\beta$ 1-AR signaling leading to dopaminergic neuron degeneration after DSP-4 pretreatment. Although  $\beta$ 1-AR could be a candidate for this, other AR may also play a role, including  $\alpha$ 1,  $\alpha$ 2 or  $\beta$ 3-AR.  $\beta$ 1-AR signaling is also associated with neuroprotection in other neurological disorders [29–31]. However, it is unknown the mechanisms by which  $\beta$ 1-AR signaling mediates neuroprotection or neurodegeneration in the brain and more studies are needed to assess the effect of  $\beta$ 1-AR signaling in neuronal survival in other PD models.

To our knowledge, few studies have shown that  $\beta$ 2-AR signaling is neuroprotective in neurotoxin mouse models of PD [16, 18, 35]. We found that in  $\alpha$ -SYN-mediated damage stimulation of  $\beta$ 2-AR by clenbuterol reduced neuroinflammation and neurodegeneration. The mechanism(s) driving dopaminergic neuron protection after increased  $\beta$ 2-AR signaling and the cells involved are still unknown. In the neurotoxin-based model of PD, one group suggested that  $\beta$ 2-AR signaling regulates mouse  $\alpha$ -SYN expression leading to neuroprotection [16] while a different group suggest that  $\beta$ 2-AR signaling directly reduced microglial activation [18, 35]. In our  $\alpha$ -SYN mouse model of PD, expression of  $\alpha$ -SYN is driven by the chicken beta actin (CBA) promoter and  $\alpha$ -SYN protein was present in dopaminergic neurons after clenbuterol treatment discarding the possibility that  $\beta$ 2-AR signaling is affecting the expression of  $\alpha$ -SYN directly in our mouse model of PD. On the other hand, RNAseq data after overexpression of  $\alpha$ -SYN showed the upregulation of different genes associated with innate and adaptive immune response [43], suggesting that neuroinflammation may play an important role in dopaminergic neuron degeneration in the context of  $\alpha$ -SYN neurotoxicity. In addition, microglia and T-cell mediated cell death is proposed to play a significant role in dopaminergic neuron degeneration in  $\alpha$ -SYN mouse model of PD [42, 43]. We found that  $\beta$ 2-AR signaling reduces pro-inflammatory microglia and T-cell infiltration in the SN. This suggests that enhancing  $\beta$ 2-AR signaling downregulates the neuroinflammatory response after overexpression of  $\alpha$ -SYN which is consistent with previous reports showing  $\beta$ 2-AR signaling reducing microglia activation in a neurotoxin-based model of PD [18, 35]. It is unknown which cell types the  $\beta$ 2-AR is acting on leading

to dopaminergic neuronal protection after rAAV2-h $\alpha$ -SYN injection. Neurons and different immune cells express  $\beta$ 2-AR in the CNS. We found that  $\beta$ 2-AR is expressed on TH+ neurons *in vivo* and others have reported expression of this receptor in microglia and T-cells. *In vitro* studies have shown that  $\beta$ 2-AR signaling in all these cell types has been associated with reduction of proinflammatory markers and reduced neurotoxicity [35, 53]. However, the possible role of  $\beta$ 2-AR signaling in these different cell types in mouse models of PD has not yet been explored.

To study the effects of DSP-4 and AR agonists in PD pathology we used only male mice, this should be considered in interpreting our data since sexual dimorphism has been identified in rats and mice regarding NE signaling in the brain [54, 55]. Additionally, we only use a pharmacological approach in dissecting the possible mechanism involved in DSP-4-mediated protection of dopaminergic neurons in the context of h $\alpha$ -SYN damage and off-target effects of propranolol, clenbuterol and xamoterol could be confounding variables skewing our data interpretation. Future experiments should focus on confirming the role of  $\beta$ 1-AR and  $\beta$ 2-AR signaling in PD pathology with different complementary strategies.

## Conclusions

In conclusion, using a h $\alpha$ -SYN mouse model of PD we showed that DSP-4 pretreatment protects dopaminergic neuron degeneration, likely due to an increase in extracellular NE and signaling in the brain since using propranolol a  $\beta$ -AR blocker prevented DSP-4-mediated neuroprotection. In addition, clenbuterol and not xamoterol treatment reduced neuroinflammation and dopaminergic neuron degeneration in the context of h $\alpha$ -SYN-mediated neurotoxicity. This suggests that specific  $\beta$ 2-AR agonists like clenbuterol may be beneficial therapeutics in PD, whereas our data with the  $\beta$ 1-AR agonist xamoterol indicates that  $\beta$ 1-AR activation is associated with increased dopaminergic neuron degeneration in the SN, suggesting that the use of  $\beta$ 1-AR agonists in PD patients may not be warranted.

## Abbreviations

LC  
Locus coeruleus  
NE  
Norepinephrine  
SN  
Substantia nigra  
SNpc  
Substantia nigra *pars compacta*  
PD  
Parkinson's disease  
AR  
Adrenergic receptors  
 $\alpha$ -SYN

$\alpha$ -synuclein  
NET  
Norepinephrine transporter  
CNS  
Central nervous system  
6OHDA  
6-hydroxydopamine  
DSP-4  
N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine hydrochloride  
HPLC-ED  
High-performance liquid chromatography with electrochemical detection  
AD  
Alzheimer's diseases  
LPS  
Lipopolysaccharide  
TH  
Tyrosine Hydroxylase

## **Declarations**

### **Ethics approval and consent to participate**

Human samples were not used in this study. All animal procedures were performed in accordance with the local welfare legislation and approved by the Institutional Animal Care and Use Committees at the University of Michigan.

### **Consent for publication**

Not applicable

### **Availability of data and materials**

All unique reagents generated in this study are available from the lead contact upon request and any additional information required to reanalyze the data reported in this paper is available from the lead contact upon reasonable request.

### **Competing interests**

The authors declare that they have no conflicts of interest.

### **Funding**

This research was supported by grants to D.A.L. from the National Institutes of Health, R01-HL055374, R01-AG074552, P50-NS091856, and from the American Parkinson Disease Association; and to D.T. from the Rackham Graduate School of the University of Michigan.

### **Authors' contributions**

DT designed and performed experiments, and wrote the manuscript; MW, KM, GPS and EJS performed experiments; DAL design experiments and wrote the manuscript. The authors read and approved the final manuscript.

### **Acknowledgements**

We thank the Emory HPLC Bioanalytical Core and Enrique Torres and Manuel Yepes from Emory University for making possible the HPLC-ED experiments; Roman Giger, Richard Mortensen, Geoffrey Murphy and Roger Albin for their feedback on experiments.

## **References**

1. Paredes-Rodriguez E, Vegas-Suarez S, Morera-Herreras T, De Deurwaerdere P, Miguelez C. The Noradrenergic System in Parkinson's Disease. *Frontiers in Pharmacology*. 2020;11.
2. Delaville C, Deurwaerdère PD, Benazzouz A. Noradrenaline and Parkinson's disease. *Frontiers in systems neuroscience*. 2011;5:31.
3. Zarow C, Lyness SA, Mortimer JA, Chui HC. Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. *Archives of neurology*. 2003;60(3):337–41.
4. Archer T. Noradrenergic-Dopaminergic Interactions Due to DSP-4-MPTP Neurotoxin Treatments: Iron Connection. *Current topics in behavioral neurosciences*. 2016;29:73–86.
5. Hou L, Sun F, Sun W, Zhang L, Wang Q. Lesion of the Locus Coeruleus Damages Learning and Memory Performance in Paraquat and Maneb-induced Mouse Parkinson's Disease Model. *Neuroscience*. 2019;419:129–40.
6. Yao N, Wu Y, Zhou Y, Ju L, Liu Y, Ju R, et al. Lesion of the locus coeruleus aggravates dopaminergic neuron degeneration by modulating microglial function in mouse models of Parkinson's disease. *Brain research*. 2015;1625:255–74.
7. Guimarães J, Moura E, Silva E, Aguiar P, Garrett C, Vieira-Coelho MA. Locus coeruleus is involved in weight loss in a rat model of Parkinson's disease: an effect reversed by deep brain stimulation. *Brain stimulation*. 2013;6(6):845–55.
8. Ostrock CY, Lindenbach D, Goldenberg AA, Kampton E, Bishop C. Effects of noradrenergic denervation by anti-DBH-saporin on behavioral responsiveness to L-DOPA in the hemi-parkinsonian rat. *Behav Brain Res*. 2014;270:75–85.

9. Shin E, Rogers JT, Devoto P, Björklund A, Carta M. Noradrenaline neuron degeneration contributes to motor impairments and development of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease. *Experimental Neurology*. 2014;257:25–38.
10. Szot P, Franklin A, Sikkema C, Wilkinson C, Raskind M. Sequential Loss of LC Noradrenergic and Dopaminergic Neurons Results in a Correlation of Dopaminergic Neuronal Number to Striatal Dopamine Concentration. *Frontiers in Pharmacology*. 2012;3.
11. Wang J, Zhou Y, Li K, Li X, Guo M, Peng M. A Noradrenergic Lesion Attenuates Surgery-Induced Cognitive Impairment in Rats by Suppressing Neuroinflammation. *Frontiers in Molecular Neuroscience*. 2021;14.
12. O'Donnell J, Zeppenfeld D, McConnell E, Pena S, Nedergaard M. Norepinephrine: a neuromodulator that boosts the function of multiple cell types to optimize CNS performance. *Neurochem Res*. 2012;37(11):2496–512.
13. Holland N, Robbins TW, Rowe JB. The role of noradrenaline in cognition and cognitive disorders. *Brain*. 2021;144(8):2243–56.
14. Giorgi FS, Biagioni F, Galgani A, Pavese N, Lazzeri G, Fornai F. Locus Coeruleus Modulates Neuroinflammation in Parkinsonism and Dementia. *International journal of molecular sciences*. 2020;21(22).
15. Gronich N, Abernethy DR, Auriel E, Lavi I, Rennert G, Saliba W.  $\beta$ 2-adrenoceptor agonists and antagonists and risk of Parkinson's disease. *Movement disorders: official journal of the Movement Disorder Society*. 2018;33(9):1465–71.
16. Mittal S, Bjørnevik K, Im DS, Flierl A, Dong X, Locascio JJ, et al.  $\beta$ 2-Adrenoreceptor is a regulator of the  $\alpha$ -synuclein gene driving risk of Parkinson's disease. *Science*. 2017;357(6354):891–8.
17. Hopfner F, Wod M, Höglinger GU, Blaabjerg M, Rösler TW, Kuhlenbäumer G, et al. Use of  $\beta$ 2-adrenoreceptor agonist and antagonist drugs and risk of Parkinson disease. *Neurology*. 2019;93(2):e135-e42.
18. O'Neill E, Yssel JD, McNamara C, Harkin A. Pharmacological targeting of  $\beta(2)$  -adrenoceptors is neuroprotective in the LPS inflammatory rat model of Parkinson's disease. *British journal of pharmacology*. 2020;177(2):282–97.
19. Ross SB, Stenfors C. DSP4, a Selective Neurotoxin for the Locus Coeruleus Noradrenergic System. A Review of Its Mode of Action. *Neurotoxicity Research*. 2015;27(1):15–30.
20. Qian H, Kang X, Hu J, Zhang D, Liang Z, Meng F, et al. Reversing a model of Parkinson's disease with in situ converted nigral neurons. *Nature*. 2020;582(7813):550–6.
21. Dowd E, Monville C, Torres EM, Dunnett SB. The Corridor Task: a simple test of lateralised response selection sensitive to unilateral dopamine deafferentation and graft-derived dopamine replacement in the striatum. *Brain research bulletin*. 2005;68(1–2):24–30.
22. Grealish S, Mattsson B, Draxler P, Björklund A. Characterisation of behavioural and neurodegenerative changes induced by intranigral 6-hydroxydopamine lesions in a mouse model of Parkinson's disease. *The European journal of neuroscience*. 2010;31(12):2266–78.

23. Delaville C, Chetrit J, Abdallah K, Morin S, Cardoit L, De Deurwaerdère P, et al. Emerging dysfunctions consequent to combined monoaminergic depletions in parkinsonism. *Neurobiology of Disease*. 2012;45(2):763–73.
24. Zhou J. Norepinephrine transporter inhibitors and their therapeutic potential. *Drugs Future*. 2004;29(12):1235–44.
25. Szot P, Miguelez C, White SS, Franklin A, Sikkema C, Wilkinson CW, et al. A comprehensive analysis of the effect of DSP4 on the locus coeruleus noradrenergic system in the rat. *Neuroscience*. 2010;166(1):279–91.
26. Kask A, Harro J, Tuomaine P, Rågo L, Männistö PT. Overflow of noradrenaline and dopamine in frontal cortex after [N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine] (DSP-4) treatment: in vivo microdialysis study in anaesthetized rats. *Naunyn-Schmiedeberg's archives of pharmacology*. 1997;355(2):267–72.
27. Hughes ZA, Stanford SC. A partial noradrenergic lesion induced by DSP-4 increases extracellular noradrenaline concentration in rat frontal cortex: a microdialysis study in vivo. *Psychopharmacology*. 1998;136(3):299–303.
28. Bortolozzi A, Artigas F. Control of 5-hydroxytryptamine release in the dorsal raphe nucleus by the noradrenergic system in rat brain. Role of alpha-adrenoceptors. *Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology*. 2003;28(3):421–34.
29. Coutellier L, Ardestani PM, Shamloo M.  $\beta$ 1-adrenergic receptor activation enhances memory in Alzheimer's disease model. *Annals of clinical and translational neurology*. 2014;1(5):348–60.
30. Faizi M, Bader PL, Tun C, Encarnacion A, Kleschevnikov A, Belichenko P, et al. Comprehensive behavioral phenotyping of Ts65Dn mouse model of Down syndrome: activation of  $\beta$ 1-adrenergic receptor by xamoterol as a potential cognitive enhancer. *Neurobiol Dis*. 2011;43(2):397–413.
31. Ardestani PM, Evans AK, Yi B, Nguyen T, Coutellier L, Shamloo M. Modulation of neuroinflammation and pathology in the 5XFAD mouse model of Alzheimer's disease using a biased and selective beta-1 adrenergic receptor partial agonist. *Neuropharmacology*. 2017;116:371–86.
32. Al-Majed AA, Bakheit AHH, Abdel Aziz HA, Alajmi FM, AlRabiah H. Chapter Six - Propranolol. In: Brittain HG, editor. *Profiles of Drug Substances, Excipients and Related Methodology*. 42: Academic Press; 2017. p. 287–338.
33. Furlong R, Brogden RN. Xamoterol. *Drugs*. 1988;36(4):455–74.
34. Jessen S, Solheim SA, Jacobson GA, Eibye K, Bangsbo J, Nordsborg NB, et al. Beta(2) -adrenergic agonist clenbuterol increases energy expenditure and fat oxidation, and induces mTOR phosphorylation in skeletal muscle of young healthy men. *Drug testing and analysis*. 2020;12(5):610–8.
35. Qian L, Wu HM, Chen SH, Zhang D, Ali SF, Peterson L, et al.  $\beta$ 2-adrenergic receptor activation prevents rodent dopaminergic neurotoxicity by inhibiting microglia via a novel signaling pathway. *Journal of immunology (Baltimore, Md: 1950)*. 2011;186(7):4443–54.

36. Sharma M, Flood PM.  $\beta$ -arrestin2 regulates the anti-inflammatory effects of Salmeterol in lipopolysaccharide-stimulated BV2 cells. *Journal of neuroimmunology*. 2018;325:10–9.
37. Perry VH. Innate inflammation in Parkinson's disease. *Cold Spring Harb Perspect Med*. 2012;2(9):a009373-a.
38. Hamzei Taj S, Kho W, Aswendt M, Collmann FM, Green C, Adamczak J, et al. Dynamic Modulation of Microglia/Macrophage Polarization by miR-124 after Focal Cerebral Ischemia. *J Neuroimmune Pharmacol*. 2016;11(4):733–48.
39. Zheng ZV, Wong KCG. Microglial activation and polarization after subarachnoid hemorrhage. *Neuroimmunology and Neuroinflammation*. 2019;6:1.
40. Bennett ML, Bennett FC, Liddel SA, Ajami B, Zamanian JL, Fernhoff NB, et al. New tools for studying microglia in the mouse and human CNS. *Proceedings of the National Academy of Sciences*. 2016;113(12):E1738-E46.
41. Schonhoff AM, Williams GP, Wallen ZD, Standaert DG, Harms AS. Innate and adaptive immune responses in Parkinson's disease. *Progress in brain research*. 2020;252:169–216.
42. Williams GP, Schonhoff AM, Jurkuvenaite A, Gallups NJ, Standaert DG, Harms AS. CD4 T cells mediate brain inflammation and neurodegeneration in a mouse model of Parkinson's disease. *Brain*. 2021;144(7):2047–59.
43. Karikari AA, McFleder RL, Ribechini E, Blum R, Bruttel V, Knorr S, et al. Neurodegeneration by  $\alpha$ -synuclein-specific T cells in AAV-A53T- $\alpha$ -synuclein Parkinson's disease mice. *Brain, Behavior, and Immunity*. 2022;101:194–210.
44. Grealish S, Mattsson B, Draxler P, Björklund A. Characterisation of behavioural and neurodegenerative changes induced by intranigral 6-hydroxydopamine lesions in a mouse model of Parkinson's disease. *European Journal of Neuroscience*. 2010;31(12):2266–78.
45. Song S, Liu J, Zhang F, Hong J-S. Norepinephrine depleting toxin DSP-4 and LPS alter gut microbiota and induce neurotoxicity in  $\alpha$ -synuclein mutant mice. *Scientific Reports*. 2020;10(1):15054.
46. Heneka MT, Ramanathan M, Jacobs AH, Dumitrescu-Ozimek L, Bilkei-Gorzo A, Debeir T, et al. Locus Coeruleus Degeneration Promotes Alzheimer Pathogenesis in Amyloid Precursor Protein 23 Transgenic Mice. *The Journal of Neuroscience*. 2006;26(5):1343–54.
47. Chalermphanupap T, Schroeder JP, Rorabaugh JM, Liles LC, Lah JJ, Levey AI, et al. Locus Coeruleus Ablation Exacerbates Cognitive Deficits, Neuropathology, and Lethality in P301S Tau Transgenic Mice. *The Journal of neuroscience: the official journal of the Society for Neuroscience*. 2018;38(1):74–92.
48. O'Neill E, Harkin A. Targeting the noradrenergic system for anti-inflammatory and neuroprotective effects: implications for Parkinson's disease. *Neural Regen Res*. 2018;13(8):1332–7.
49. Zou H-L, Li J, Zhou J-L, Yi X, Cao S. Effects of norepinephrine on microglial neuroinflammation and neuropathic pain. *Ibrain*. 2021;7(4):309–17.
50. 50.

51. Johnson EW, Wolfe BB, Molinoff PB. Regulation of subtypes of beta-adrenergic receptors in rat brain following treatment with 6-hydroxydopamine. *The Journal of Neuroscience*. 1989;9(7):2297.
52. Song J, Zheng L, Zhang X, Feng X, Fan R, Sun L, et al. Upregulation of  $\beta$ 1-adrenoceptors is involved in the formation of gastric dysmotility in the 6-hydroxydopamine rat model of Parkinson's disease. *Translational research: the journal of laboratory and clinical medicine*. 2014;164(1):22–31.
53. Loza MJ, Foster S, Peters SP, Penn RB. Beta-agonists modulate T-cell functions via direct actions on type 1 and type 2 cells. *Blood*. 2006;107(5):2052–60.
54. Curtis AL, Bethea T, Valentino RJ. Sexually Dimorphic Responses of the Brain Norepinephrine System to Stress and Corticotropin-Releasing Factor. *Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology*. 2006;31(3):544–54.
55. Sun P, Wang J, Zhang M, Duan X, Wei Y, Xu F, et al. Sex-Related Differential Whole-Brain Input Atlas of Locus Coeruleus Noradrenaline Neurons. *Frontiers in Neural Circuits*. 2020;14.

## Figures




Figure 1

**DSP-4 treatment increases dopaminergic neuron degeneration in the 6OHDA model of PD.** (A) Representative images of the SN showing dopaminergic neurons degeneration in the injected SN (TH, white) and (B) quantification of TH+ neurons in coronal sections of the SN 4 weeks after 6OHDA injection of WT mice treated with Saline, DSP-4 or Desipramine + DSP-4. (C) NE and serotonin tissue levels measured by HPLC-ED in the cortex and SN of WT mice 4 weeks after DSP-4 or saline treatment. (D)

Representative images of the LC showing noradrenergic neurons (TH, cyan) and quantification of TH+ noradrenergic neurons in coronal sections of the LC 4 weeks after DSP-4 or saline injection in WT mice. Data is shown as mean values  $\pm$  SEM, N.S.=not significant, \* $p$ <0.05; \*\* $p$ <0.01; \*\*\* $p$ <0.001. 1-way ANOVA followed by Tukey post hoc test; 2-tailed t-test. Scale bar= 500  $\mu$ m.




Figure 2

**DSP-4 treatment protects dopaminergic neurons degeneration in the SN from hα-SYN-mediated degeneration.** (A) Representative images of the SN showing dopaminergic neurons degeneration in the injected SN (TH, white) and (B) quantification of TH+ dopaminergic neurons in coronal sections of the SN 4 weeks after rAAV2-hα-SYN injection in WT mice pretreated with Saline, DSP-4 or Desipramine + DSP-4. (C) NE tissue levels measured by HPLC-ED in the cortex of WT mice 4 weeks after DSP-4, Desipramine +

DSP-4 or saline treatment. Data is shown as mean values  $\pm$  SEM, N.S=not significant, \*\* $p < 0.01$ ; \*\*\* $p < 0.001$ ; \*\*\*\* $p < 0.0001$ . 1-way ANOVA followed by Tukey post hoc test. Scale bar= (A) 500  $\mu\text{m}$ .




Figure 3

**Blocking  $\beta$ -adrenergic receptors inhibits DSP-4-mediated dopaminergic neurons protection after ha-SYN overexpression.** (A) Representative images of the SN showing dopaminergic neuron degeneration in the injected SN (TH, white) and (B) quantification of TH<sup>+</sup> dopaminergic neurons in coronal sections of the SN 4 weeks after rAAV2-h $\alpha$ -SYN injection of WT mice in the different experimental conditions. Data is shown as mean values  $\pm$  SEM, N.S=not significant, \* $p < 0.05$ ; \*\* $p < 0.01$ . 1-way ANOVA followed by Tukey post hoc test. Scale bar= (A) 500  $\mu\text{m}$ .




Figure 4

**$\beta$ -2 but not a  $\beta$ -1 AR agonist protects dopaminergic neurons in the SN from h $\alpha$ -SYN-mediated neurotoxicity.** (A) Representative images of the SN showing dopaminergic neurons degeneration in the injected SN (TH, white) and (B) quantification of TH<sup>+</sup> dopaminergic neurons in coronal sections of the SN 4 weeks after rAAV2-h $\alpha$ -SYN injection in WT mice treated daily with saline, Xamoterol or Clenbuterol. Data is shown as mean values  $\pm$  SEM, N.S.=not significant, \* $p$ <0.05; \*\*\* $p$ <0.001. 1-way ANOVA followed by Tukey post hoc test. Scale bar= 500  $\mu$ m.





Figure 5

**Opposing effects of  $\beta$ -1 and  $\beta$ -2 AR signaling in microglia activation after ha-SYN overexpression.**

Coronal sections of the SN showing (A) CD16/32 and (B) TMEM119 staining and (C) their respective quantifications indicating fluorescence intensity fold change relative to saline-treated WT mice 4 weeks after rAAV2-ha-SYN injection in clenbuterol and xamoterol treated WT mice. (D) Confocal images of the SN showing TMEM119 (red), TH (white) and CD16/32 (green) staining 4 weeks after rAAV2-ha-SYN

injection in WT mice treated with saline, clenbuterol or xamoterol daily. Arrows indicate TMEM119 and CD16/32 colocalization. Confocal images are shown as maximum intensity projections. Data is shown as mean values  $\pm$  SEM, N.S.=not significant, \* $p < 0.05$ ; \*\* $p < 0.01$ . 1-way ANOVA followed by Tukey post hoc test. Scale bar= (A-B) 500  $\mu$ m (D) 20  $\mu$ m.



## Figure 6

**Clenbuterol reduce T-cell infiltration and rescues behavioral deficits after h $\alpha$ -SYN overexpression in the SN.** (A) Representative images of the SN showing CD3 (red) and TH (white) staining and (B) confocal close up showing CD3+ cells in contact with TH cell bodies and axons (arrows). (C) Quantification of CD3+ T cells associated with the SNpc 4 weeks after rAAV2-h $\alpha$ -SYN injection in WT mice treated with saline, Clenbuterol or Xamoterol daily. (D) Quantification of sensorimotor bias in a corridor task 4 weeks after rAAV2-h $\alpha$ -SYN injection in WT treated with saline or clenbuterol daily. Black horizontal dash line represents the expected % of contralateral explorations in an uninjured WT mouse. Confocal images are shown as maximum intensity projections. Data is shown as mean values  $\pm$  SEM, N.S=not significant, \* $p$ <0.05; \*\*\*\* $p$ <0.0001. 1-way ANOVA followed by Tukey post hoc test. Scale bar= (A-B) 500  $\mu$ m (D) 20  $\mu$ m.

## Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [Additionalfile1.pdf](#)